Ranbaxy Laboratories settles dispute with Cephalon
Ranbaxy Laboratories, headquartered in India, says it has settled its US patent infringement dispute over Provigil (modafinil) tablets with Cephalon.
Ranbaxy Laboratories, headquartered in India, says it has settled its US patent infringement dispute over Provigil (modafinil) tablets with Cephalon.
Cephalon will grant Ranbaxy a non-exclusive royalty-bearing right to market and sell a generic version of Provigil in the US, effective in October 2011 in the absence of a pediatric extension for Provigil (which would delay the entry date by six months to April, 2012). An earlier entry by Ranbaxy may occur based upon the entry of another generic version of Provigil.
The companies also agreed to a series of business arrangements related to modafinil. Ranbaxy has agreed to give to Cephalon a non-exclusive license, effective immediately, to some worldwide intellectual property rights related to modafinil in exchange for milestone payments. Cephalon also has agreed an arrangement with Ranbaxy relating to the supply of the active pharmaceutical ingredient modafinil.
The terms of the agreement were not disclosed, but are subject to review by the US Federal Trade Commission.